We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Syncona Limited | LSE:SYNC | London | Ordinary Share | GG00B8P59C08 | ORD NPV |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.60 | -1.31% | 120.40 | 120.40 | 122.20 | 120.80 | 120.20 | 120.20 | 15,741 | 09:48:45 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Trust,ex Ed,religious,charty | -39.79M | -56.02M | -0.0840 | -14.33 | 802.75M |
From May 2019 to May 2024
TIDMSYNC
RNS Number : 4402A
Syncona Limited
21 January 2020
Syncona Limited
Notice of Capital Markets Day
21 January 2020
Syncona Ltd, a leading healthcare company focused on founding, building and funding global leaders in life sciences, will host a Capital Markets Day for investors and analysts on the afternoon of Tuesday, 4 February 2020 in Central London.
Syncona's management team will present Syncona's strategy and long-term vision for the business. This will be followed by panel discussions with leaders from Syncona's portfolio companies on translating exceptional science, the future of cell therapy, and building a commercial gene therapy platform.
Presentations and panels are taking place from 13:00 - 17:00 GMT. A live webcast of the Capital Markets Day will be made available on the Investor Relations section of the company's website at www.synconaltd.com
For further information and to register to attend, please contact events@synconaltd.com.
[ENDS]
Enquiries
Syncona Ltd
Siobhan Weaver / Annabel Clay
Tel : +44 (0) 20 3981 7940
FTI Consulting
Ben Atwell / Natalie Garland-Collins / Tim Stamper
Tel: +44 (0) 20 3727 1000
About Syncona
Syncona is a leading FTSE250 healthcare company focused on founding, building and funding a portfolio of global leaders in life science. Our vision is to build a sustainable, diverse portfolio of 15 - 20 companies focused on delivering transformational treatments to patients in truly innovative areas of healthcare, through which we are seeking to deliver strong risk-adjusted returns for shareholders.
We seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses. We take a long-term view, underpinned by a strategic capital base which provides us with control and flexibility over the management of our portfolio. We focus on delivering dramatic efficacy for patients in areas of high unmet need.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
MSCVFLBLBFLZBBB
(END) Dow Jones Newswires
January 21, 2020 03:45 ET (08:45 GMT)
1 Year Syncona Chart |
1 Month Syncona Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
